|Last Price$9.29||Day Change (%)0.00%|
|Open Price$9.29||Day Change ($)0.00|
|Day Range9.29–9.29||52-Week Range9.03–9.42|
As of Fri 04/17/2015 | USD
AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan
Janssen Highlights Hepatitis C Virus Development Programme at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)
Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015
Medivir: New simeprevir data will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL)
AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015
Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...
Three stocks we think investors should be wary of.